| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4260a256b5f28ea7d92b4c1f5b921d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-115 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-115 |
| filingDate |
2001-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00a759e5b4366ce3927629570d1bf642 |
| publicationDate |
2001-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2410028-A1 |
| titleOfInvention |
Ligands specific for an isoform of the prion protein |
| abstract |
Prion protein, PrP, ligands are provided, especially protease resistant and nuclease resistant ligands. Ligands selective for isoforms such as PrPSC can be prepared. In a related aspect, the PrP ligands are used in diagnostic tests for PrP. The ligands also have potential for a role in the development of therapeutic methods for treatment of TSEs. |
| priorityDate |
2000-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |